Cybin D/B/A Helus Pharma (NASDAQ:HELP) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds.
The seventh stock on our list of most promising stocks is Cybin D/B/A Helus Pharma.
TheFly reported on February 2 that Jefferies initiated coverage of HELP with a Buy rating and a $22 price target and also highlighted significant upside potential. The firm has identified three key catalysts for 2026 which includes the recent appointment of a permanent CEO, which is seen as a crucial operational and strategic milestone supporting stock appreciation; the lead asset, HLP003, an oral d-psilocin therapy for adjunct major depressive disorder, has a roughly 60% probability of success in its Phase III trial, which could drive a 100%-200% share rally; and HLP004, an intramuscular d-DMT therapy, is anticipated to report de-risking Phase II data in Q1.
Furthermore, Cybin D/B/A Helus Pharma announced Q3 fiscal 2026 results on February 13 for the quarter that concluded on December 31, 2025, showing $195.1 million in cash on hand before any post-quarter adjustments. To advance a multi-asset neuroscience portfolio throughout many stages of development, the business placed a strong emphasis on maintaining disciplined execution across its clinical and operational priorities. The HLP003 Phase 3 and HLP004 Phase 2 studies are still making progress, with an emphasis on clinical strategies that are repeatable and scalable. HELP is well-positioned to deliver on future clinical milestones and generate long-term shareholder value thanks to its solid balance sheet and continuous clinical advances.
Cybin D/B/A Helus Pharma is a clinical‑stage psychedelic biotechnology company developing innovative psilocybin‑based and novel psychotherapeutic compounds and delivery systems to treat mental health conditions with science‑driven, evidence‑based approaches.
READ NEXT: 12 Unstoppable Dividend Stocks to Buy According to Analysts and Dividend Champions, Contenders and Challengers list: 15 Highest Yielding Stocks.
